Clinical Trials Logo
  1. Home
  2. Leptomeningeal Metastasis
  3. NCT06296745

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Leptomeningeal Metastasis Clinical Trial

Official title:
An Open-label, Single-arm, Phase II Trial of Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After a Double Dose of Third-generation TKIs, Including Osimertinib

Clinical Trial Summary

Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patients with leptomeningeal metastases from NSCLC. It has been recommended as the preferred drug for intrathecal chemotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines. Tyrosine kinase inhibitors (TKIs) play a promising role in treating non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations. An international multi-center clinical study published in 2019 confirmed that double dose of osimertinib showed significant improvement in leptomeningeal metastases from NSCLC with EGFR exon 19 deletion or exon 21 L858R/T790M mutation. It makes TKIs the mainstay of treatment for patients with EGFR-mutant NSCLC with leptomeningeal metastases. However, the choice of treatment after resistance to targeted therapy is a hot topic in clinical practice, with 78% of patients in the study above who responded to double-dose osimertinib still showing progression at the time of follow-up. The purpose of this study was to observe the safety and efficacy of intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma that progressed after a double dose of a third-generation TKI such as osimertinib.

Clinical Trial Description

This study is a single arm, open and phase II clinical trial. Consecutive patients with leptomeningeal metastases from lung adenocarcinoma that progressed after a double dose of a third-generation TKI such as osimertinib are enrolled in this study. Concomitant regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 15 mg, plus dexamethasone 5 mg, twice a week for 2 weeks as an induction phase, followed by once a week for 4 weeks as a consolidation phase. Thereafter, the maintenance phase is once a month). The RANO proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06296745
Study type Interventional
Source Guangzhou Medical University
Contact Zhenyu Pan
Phone +8615804302753
Email dr-zypan@163.com
Status Not yet recruiting
Phase Phase 2
Start date March 20, 2024
Completion date March 20, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT04178343 - Tomotherapy for Leptomeningeal Metastases N/A
Recruiting NCT04425681 - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Recruiting NCT02803619 - A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis N/A
Recruiting NCT05746754 - Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis N/A
Not yet recruiting NCT04148898 - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis Phase 2
Completed NCT04420598 - DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease Phase 2
Completed NCT02071056 - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
Not yet recruiting NCT05805631 - Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC Phase 2
Recruiting NCT05385185 - Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer Phase 2
Terminated NCT04729348 - Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Phase 2
Recruiting NCT06304441 - Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer N/A
Recruiting NCT04778800 - A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) N/A
Not yet recruiting NCT06282874 - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Phase 4
Not yet recruiting NCT04356222 - Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Phase 4
Not yet recruiting NCT04356118 - Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Phase 4
Not yet recruiting NCT04944069 - Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis N/A
Withdrawn NCT03974204 - Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis. N/A